Comparison of cytotoxicities and anti-allergic effects of topical ocular dual-action anti-allergic agents
BACKGROUND: To investigate the cytotoxicities of the topical ocular dual-action anti-allergic agents (alcaftadine 0.25%, bepotastine besilate 1.5%, and olopatadine HCL 0.1%) on human corneal epithelial cells (HCECs) and their anti-allergic effects on cultured conjunctival epithelial cells.
METHODS: A Methylthiazolyltetrazolium(MTT)-based calorimetric assay was used to assess cytotoxicities using HCECs at concentrations of 10, 20 or 30% for exposure durations of 30 min, 1 h, 2 h, 12 h or 24 h. Cellular morphologies were evaluated by inverted phase-contrast and electron microscopy. Wound widths were measured 2 h, 18 h, or 24 h after confluent HCECs monolayers were scratched. Realtime PCR was used to quantify anti-allergic effects on cultured human conjunctival cells, in which allergic reactions were induced by treating them with Aspergillus antigen.
RESULTS: Cell viabilities decreased in time- and concentration-dependent manners. Cells were detached from dishes and showed microvilli loss, cytoplasmic vacuoles, and nuclear condensation when exposed to antiallergic agents; alcaftadine was found to be least cytotoxic. Alcaftadine treated HCECs monolayers showed the best wound healing followed by bepotastine and olopatadine (p < 0.0001). All agents significantly reduced the gene expressions of allergic cytokines (IL-5, IL-25, eotaxin, thymus and activation-regulated chemokine, and thymic stromal lymphopoietin) and alcaftadine had the greatest effect (p < 0.0001 in all cases).
CONCLUSIONS: Alcaftadine seems to have less side effects and better therapeutic effects than the other two anti-allergic agents tested. It may be more beneficial to use less toxic agents for patients with ocular surface risk factors or presumed symptoms of toxicity.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2019 |
|---|---|
| Erschienen: |
2019 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:19 |
|---|---|
| Enthalten in: |
BMC ophthalmology - 19(2019), 1 vom: 08. Nov., Seite 217 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Kim, Sung Il [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 09.03.2020 Date Revised 09.03.2020 published: Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1186/s12886-019-1228-5 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM303073969 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM303073969 | ||
| 003 | DE-627 | ||
| 005 | 20231225112049.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2019 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1186/s12886-019-1228-5 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1010.xml |
| 035 | |a (DE-627)NLM303073969 | ||
| 035 | |a (NLM)31703568 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Kim, Sung Il |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Comparison of cytotoxicities and anti-allergic effects of topical ocular dual-action anti-allergic agents |
| 264 | 1 | |c 2019 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 09.03.2020 | ||
| 500 | |a Date Revised 09.03.2020 | ||
| 500 | |a published: Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a BACKGROUND: To investigate the cytotoxicities of the topical ocular dual-action anti-allergic agents (alcaftadine 0.25%, bepotastine besilate 1.5%, and olopatadine HCL 0.1%) on human corneal epithelial cells (HCECs) and their anti-allergic effects on cultured conjunctival epithelial cells | ||
| 520 | |a METHODS: A Methylthiazolyltetrazolium(MTT)-based calorimetric assay was used to assess cytotoxicities using HCECs at concentrations of 10, 20 or 30% for exposure durations of 30 min, 1 h, 2 h, 12 h or 24 h. Cellular morphologies were evaluated by inverted phase-contrast and electron microscopy. Wound widths were measured 2 h, 18 h, or 24 h after confluent HCECs monolayers were scratched. Realtime PCR was used to quantify anti-allergic effects on cultured human conjunctival cells, in which allergic reactions were induced by treating them with Aspergillus antigen | ||
| 520 | |a RESULTS: Cell viabilities decreased in time- and concentration-dependent manners. Cells were detached from dishes and showed microvilli loss, cytoplasmic vacuoles, and nuclear condensation when exposed to antiallergic agents; alcaftadine was found to be least cytotoxic. Alcaftadine treated HCECs monolayers showed the best wound healing followed by bepotastine and olopatadine (p < 0.0001). All agents significantly reduced the gene expressions of allergic cytokines (IL-5, IL-25, eotaxin, thymus and activation-regulated chemokine, and thymic stromal lymphopoietin) and alcaftadine had the greatest effect (p < 0.0001 in all cases) | ||
| 520 | |a CONCLUSIONS: Alcaftadine seems to have less side effects and better therapeutic effects than the other two anti-allergic agents tested. It may be more beneficial to use less toxic agents for patients with ocular surface risk factors or presumed symptoms of toxicity | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Allergic conjunctivitis | |
| 650 | 4 | |a Cytotoxicity | |
| 650 | 4 | |a Topical anti-allergic agents | |
| 650 | 7 | |a Anti-Allergic Agents |2 NLM | |
| 650 | 7 | |a Benzazepines |2 NLM | |
| 650 | 7 | |a Imidazoles |2 NLM | |
| 650 | 7 | |a Piperidines |2 NLM | |
| 650 | 7 | |a Pyridines |2 NLM | |
| 650 | 7 | |a Olopatadine Hydrochloride |2 NLM | |
| 650 | 7 | |a 2XG66W44KF |2 NLM | |
| 650 | 7 | |a bepotastine besilate |2 NLM | |
| 650 | 7 | |a 6W18MO1QR3 |2 NLM | |
| 650 | 7 | |a alcaftadine |2 NLM | |
| 650 | 7 | |a 7Z8O94ECSX |2 NLM | |
| 700 | 1 | |a Park, Choul Yong |e verfasserin |4 aut | |
| 700 | 1 | |a Fordjuor, Gladys |e verfasserin |4 aut | |
| 700 | 1 | |a Lee, Jong Heon |e verfasserin |4 aut | |
| 700 | 1 | |a Lee, Jong Soo |e verfasserin |4 aut | |
| 700 | 1 | |a Lee, Ji Eun |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t BMC ophthalmology |d 2001 |g 19(2019), 1 vom: 08. Nov., Seite 217 |w (DE-627)NLM11233282X |x 1471-2415 |7 nnns |
| 773 | 1 | 8 | |g volume:19 |g year:2019 |g number:1 |g day:08 |g month:11 |g pages:217 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1186/s12886-019-1228-5 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 19 |j 2019 |e 1 |b 08 |c 11 |h 217 | ||